Abbott's SonicForce coronary IVL trial meets primary safety and effectiveness endpoints

Abbott reported that its TECTONIC trial of the investigational SonicForce Coronary IVL system met primary safety and effectiveness endpoints, with 0.3% 30-day target lesion failure and 97% procedural success in 335 patients.

Detected & updated continuously · Source: Nebula